Advanced Materials,
Год журнала:
2023,
Номер
unknown
Опубликована: Авг. 10, 2023
Rapid
advancements
in
materials
science
and
nanotechnology,
intertwined
with
oncology,
have
positioned
photothermal
therapy
(PTT)
as
a
promising
noninvasive
treatment
strategy
for
cancer.
The
breast's
superficial
anatomical
location
aesthetic
significance
render
breast
cancer
particularly
pertinent
candidate
the
clinical
application
of
PTT
following
melanoma.
This
review
comprehensively
explores
research
conducted
on
various
types
nanoparticles
employed
elaborates
their
specific
roles
mechanisms
action.
integration
existing
therapies
is
scrutinized,
underscoring
its
potential
synergistic
outcomes.
Additionally,
underlying
consequential
modifications
to
tumor
microenvironment
after
are
elaborated
from
medical
perspective.
Future
directions
suggested,
an
emphasis
development
integrative
platforms
that
combine
multiple
therapeutic
approaches
optimization
nanoparticle
synthesis
enhanced
efficacy.
goal
push
boundaries
toward
comprehensive,
clinically
applicable
The Journal of Urology,
Год журнала:
2023,
Номер
210(1), С. 46 - 53
Опубликована: Апрель 25, 2023
The
summary
presented
herein
covers
recommendations
on
the
early
detection
of
prostate
cancer
and
provides
a
framework
to
facilitate
clinical
decision-making
in
implementation
screening,
biopsy,
follow-up.
This
is
Part
I
two-part
series
that
focuses
screening.
Please
refer
II
for
discussion
initial
repeat
biopsies
as
well
biopsy
technique.
systematic
review
utilized
inform
this
guideline
was
conducted
by
an
independent
methodological
consultant.
based
searches
Ovid
MEDLINE
Embase
Cochrane
Database
Systematic
Reviews
(January
1,
2000-November
21,
2022).
Searches
were
supplemented
reviewing
reference
lists
relevant
articles.
Early
Detection
Prostate
Cancer
Panel
developed
evidence-
consensus-based
statements
provide
guidance
Prostate-specific
antigen
(PSA)-based
screening
combination
with
shared
(SDM)
recommended.
Current
data
regarding
risk
from
population-based
cohorts
basis
longer
intervals
tailored
use
available
online
calculators
encouraged.
CA A Cancer Journal for Clinicians,
Год журнала:
2023,
Номер
73(6), С. 620 - 652
Опубликована: Июнь 17, 2023
Abstract
Small
cell
lung
cancer
(SCLC)
is
characterized
by
rapid
growth
and
high
metastatic
capacity.
It
has
strong
epidemiologic
biologic
links
to
tobacco
carcinogens.
Although
the
majority
of
SCLCs
exhibit
neuroendocrine
features,
an
important
subset
tumors
lacks
these
properties.
Genomic
profiling
SCLC
reveals
genetic
instability,
almost
universal
inactivation
tumor
suppressor
genes
TP53
RB1
,
a
mutation
burden.
Because
early
metastasis,
only
small
fraction
patients
are
amenable
curative‐intent
resection,
individuals
require
adjuvant
platinum‐etoposide
chemotherapy.
Therefore,
vast
currently
being
treated
with
chemoradiation
or
without
immunotherapy.
In
disease
confined
chest,
standard
therapy
includes
thoracic
radiotherapy
concurrent
Patients
(extensive‐stage)
combination
chemotherapy
plus
immunotherapy
anti‐programmed
death‐ligand
1
monoclonal
antibody.
initially
very
responsive
platinum‐based
chemotherapy,
responses
transient
because
development
drug
resistance.
recent
years,
authors
have
witnessed
accelerating
pace
insights
into
disease,
leading
redefinition
classification
scheme.
This
emerging
knowledge
molecular
subtypes
potential
define
unique
therapeutic
vulnerabilities.
Synthesizing
new
discoveries
current
biology
clinical
management
may
lead
unprecedented
advances
in
patient
care.
Here,
present
overview
multimodal
approaches
SCLC,
special
focus
on
illuminating
how
advancements
research
could
accelerate
development.
Pharmacological Research,
Год журнала:
2024,
Номер
200, С. 107059 - 107059
Опубликована: Янв. 11, 2024
Owing
to
the
dysregulation
of
protein
kinase
activity
in
many
diseases
including
cancer,
this
enzyme
family
has
become
one
most
important
drug
targets
21st
century.
There
are
80
FDA-approved
therapeutic
agents
that
target
about
two
dozen
different
kinases
and
seven
these
drugs
were
approved
2023.
Of
drugs,
thirteen
protein-serine/threonine
kinases,
four
directed
against
dual
specificity
(MEK1/2),
twenty
block
nonreceptor
protein-tyrosine
43
inhibit
receptor
kinases.
The
data
indicate
69
prescribed
for
treatment
neoplasms.
Six
(abrocitinib,
baricitinib,
deucravacitinib,
ritlecitinib,
tofacitinib,
upadacitinib)
used
inflammatory
(atopic
dermatitis,
rheumatoid
arthritis,
psoriasis,
alopecia
areata,
ulcerative
colitis).
nearly
multiple
diseases.
following
received
FDA
approval
2023:
capivasertib
(HER2-positive
breast
cancer),
fruquintinib
(metastatic
colorectal
momelotinib
(myelofibrosis),
pirtobrutinib
(mantle
cell
lymphoma,
chronic
lymphocytic
leukemia,
small
lymphoma),
quizartinib
(Flt3-mutant
acute
myelogenous
leukemia),
repotrectinib
(ROS1-positive
lung
ritlecitinib
(alopecia
areata).
All
orally
effective
with
exception
netarsudil,
temsirolimus,
trilaciclib.
This
review
summarizes
physicochemical
properties
all
molecule
inhibitors
molecular
weight,
number
hydrogen
bond
donors/acceptors,
polar
surface
area,
potency,
solubility,
lipophilic
efficiency,
ligand
efficiency.
CA A Cancer Journal for Clinicians,
Год журнала:
2023,
Номер
74(1), С. 50 - 81
Опубликована: Ноя. 1, 2023
Abstract
Lung
cancer
is
the
leading
cause
of
mortality
and
person‐years
life
lost
from
among
US
men
women.
Early
detection
has
been
shown
to
be
associated
with
reduced
lung
mortality.
Our
objective
was
update
American
Cancer
Society
(ACS)
2013
screening
(LCS)
guideline
for
adults
at
high
risk
cancer.
The
intended
provide
guidance
health
care
providers
their
patients
who
are
due
a
history
smoking.
ACS
Guideline
Development
Group
(GDG)
utilized
systematic
review
LCS
literature
commissioned
Preventive
Services
Task
Force
2021
recommendation
update;
second
years
since
quitting
smoking
(YSQ);
published
2021;
two
Intervention
Surveillance
Modeling
Network‐validated
models
assess
benefits
harms
screening;
an
epidemiologic
modeling
analysis
examining
effect
YSQ
aging
on
risk;
updated
benefit‐to‐radiation‐risk
ratios
follow‐up
examinations.
GDG
also
examined
disease
burden
data
National
Institute’s
Surveillance,
Epidemiology,
End
Results
program.
Formulation
recommendations
based
quality
evidence
judgment
(incorporating
values
preferences)
about
balance
harms.
judged
that
overall
moderate
sufficient
support
strong
individuals
meet
eligibility
criteria.
in
women
aged
50–80
reduction
deaths
across
range
study
designs,
inferential
supports
older
than
80
good
health.
recommends
annual
low‐dose
computed
tomography
asymptomatic
currently
smoke
or
formerly
smoked
have
≥20
pack‐year
(
,
).
Before
decision
made
initiate
LCS,
should
engage
shared
decision‐making
discussion
qualified
professional.
For
smoked,
number
not
criterion
begin
stop
screening.
Individuals
receive
counseling
quit
connected
cessation
resources.
comorbid
conditions
substantially
limit
expectancy
screened.
These
considered
by
discussions
LCS.
If
fully
implemented,
these
likelihood
significantly
reducing
death
suffering
United
States.
The Innovation,
Год журнала:
2024,
Номер
5(3), С. 100625 - 100625
Опубликована: Апрель 9, 2024
Identifying
genes
with
prognostic
significance
that
can
act
as
biomarkers
in
solid
tumors
help
stratify
patients
and
uncover
novel
therapy
targets.
Here,
our
goal
was
to
expand
previous
ranking
analysis
of
survival-associated
various
include
colon
cancer
specimens
available
transcriptomic
clinical
data.
A
Gene
Expression
Omnibus
search
performed
identify
datasets
data
raw
gene
expression
measurements.
combined
database
set
up
integrated
into
Kaplan-Meier
plotter,
making
it
possible
changes
linked
altered
survival.
As
a
demonstration
the
utility
platform,
most
powerful
overall
survival
were
identified
using
uni-
multivariate
Cox
regression
analysis.
The
includes
2,137
tumor
samples
from
17
independent
cohorts.
significant
associated
relapse-free
false
discovery
rate
below
1%
carcinoma
Journal of Hematology & Oncology,
Год журнала:
2023,
Номер
16(1)
Опубликована: Авг. 28, 2023
Triple-negative
breast
cancer
(TNBC),
a
highly
aggressive
subtype
of
cancer,
negatively
expresses
estrogen
receptor,
progesterone
and
the
human
epidermal
growth
factor
receptor
2
(HER2).
Although
chemotherapy
is
main
form
treatment
for
patients
with
TNBC,
effectiveness
TNBC
still
limited.
The
search
more
effective
therapies
urgent.
Multiple
targeted
therapeutic
strategies
have
emerged
according
to
specific
molecules
signaling
pathways
expressed
in
TNBC.
These
include
PI3K/AKT/mTOR
inhibitors,
Notch
poly
ADP-ribose
polymerase
antibody-drug
conjugates.
Moreover,
immune
checkpoint
example,
pembrolizumab,
atezolizumab,
durvalumab,
are
widely
explored
clinic.
We
summarize
recent
advances
therapy
immunotherapy
aim
serving
as
reference
development
individualized
future.
Abstract
Skin
cancer
is
a
global
threat
to
the
healthcare
system
and
estimated
incline
tremendously
in
next
20
years,
if
not
diagnosed
at
an
early
stage.
Even
though
it
curable
stage,
novel
drug
identification,
clinical
success,
resistance
another
major
challenge.
To
bridge
gap
bring
effective
treatment,
important
understand
etiology
of
skin
carcinoma,
mechanism
cell
proliferation,
factors
affecting
growth,
resistance.
The
current
article
focusses
on
understanding
structural
diversity
cancers,
treatments
available
till
date
including
phytocompounds,
chemotherapy,
radiotherapy,
photothermal
therapy,
surgery,
combination
molecular
targets
associated
with
growth
metastasis,
special
emphasis
nanotechnology-based
approaches
for
downregulating
deleterious
disease.
A
detailed
analysis
respect
types
nanoparticles
their
scope
overcoming
multidrug
as
well
trials
has
been
discussed.
Graphical
Colorectal
cancer
(CRC)
is
the
most
common
of
digestive
system
with
high
mortality
and
morbidity
rates.
Gut
microbiota
found
in
intestines,
especially
colorectum,
has
structured
crosstalk
interactions
host
that
affect
several
physiological
processes.
The
gut
include
CRC-promoting
bacterial
species,
such
as
Fusobacterium
nucleatum,
Escherichia
coli,
Bacteroides
fragilis,
CRC-protecting
Clostridium
butyricum,
Streptococcus
thermophilus,
Lacticaseibacillus
paracasei,
which
along
other
microorganisms,
viruses
fungi,
play
critical
roles
development
CRC.
Different
features
are
identified
patients
early-onset
CRC,
combined
different
patterns
between
fecal
intratumoral
microbiota.
may
be
beneficial
diagnosis
treatment
CRC;
some
bacteria
serve
biomarkers
while
others
regulators
chemotherapy
immunotherapy.
Furthermore,
metabolites
produced
by
essential
CRC
cells.
Harmful
primary
bile
acids
short-chain
fatty
acids,
whereas
others,
including
ursodeoxycholic
acid
butyrate,
impede
tumor
progression.
This
review
focuses
on
its
metabolites,
their
potential
development,
diagnosis,
Annals of Oncology,
Год журнала:
2023,
Номер
34(11), С. 970 - 986
Опубликована: Сен. 6, 2023
The
18th
St
Gallen
International
Breast
Cancer
Conference
held
in
March
2023,
Vienna,
Austria,
assessed
significant
new
findings
for
local
and
systemic
therapies
early
breast
cancer
with
a
focus
on
the
evaluation
of
multimodal
treatment
options.
emergence
more
effective,
innovative
agents
both
preoperative
(primary
or
neoadjuvant)
post-operative
(adjuvant)
settings
has
underscored
pivotal
role
multidisciplinary
approach
decision
making,
particularly
when
selecting
therapy
an
individual
patient.
importance
discussions
regarding
clinical
benefits
interventions
was
explicitly
emphasized
by
consensus
panel
as
integral
part
developing
optimal
plan
'right'
degree
intensity
duration.
panelists
focused
controversies
surrounding
management
common
ductal/no
special
type
lobular
histology,
which
account
vast
majority
tumors.
expert
opinion
based
interpretations
available
data,
well
current
practices
their
professional
environments,
personal
socioeconomic
factors
affecting
patients,
cognizant
varying
reimbursement
accessibility
constraints
around
world.
strongly
advocated
patient
participation
well-designed
studies
whenever
feasible.
With
these
considerations
mind,
Consensus
aims
to
offer
guidance
clinicians
appropriate
treatments
early-stage
assist
balancing
realistic
trade-offs
between
benefit
toxicity,
enabling
patients
make
well-informed
choices
through
shared
decision-making
process.
